Insider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) CEO Acquires $100,010.00 in Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc bought 73,000 shares of the stock in a transaction dated Monday, September 14th. The stock was purchased at an average price of $1.37 per share, with a total value of $100,010.00. Following the acquisition, the chief executive officer directly owned 1,049,121 shares in the company, valued at approximately $1,437,295.77. The trade was a 7.48% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

MAIA Biotechnology Stock Performance

MAIA stock opened at $1.40 on Friday. The stock has a market cap of $85.16 million, a PE ratio of -2.26 and a beta of 0.25. MAIA Biotechnology, Inc. has a 12 month low of $0.87 and a 12 month high of $3.19. The company has a 50-day moving average price of $1.35 and a 200 day moving average price of $1.37.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). Sell-side analysts forecast that MAIA Biotechnology, Inc. will post -0.54 EPS for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

Institutional investors and hedge funds have recently modified their holdings of the business. Centric Wealth Management purchased a new stake in shares of MAIA Biotechnology during the second quarter valued at $1,107,000. Cable Car Capital LP purchased a new position in MAIA Biotechnology in the 2nd quarter worth about $741,000. BlackRock Inc. purchased a new position in MAIA Biotechnology in the 2nd quarter worth about $580,000. Corsair Capital Management L.P. bought a new stake in MAIA Biotechnology during the 1st quarter valued at about $140,000. Finally, Susquehanna International Group LLP bought a new stake in MAIA Biotechnology during the 2nd quarter valued at about $51,000. 5.65% of the stock is owned by institutional investors.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research centers on telomeres, protective structures at the ends of chromosomes that are maintained in many cancer cells through telomerase activity.

MAIA’s lead investigational product is THIO, also known as 6-thio-2′-deoxyguanosine (6-thio-dG). The compound is designed to be activated in telomerase-positive cancer cells, promoting telomere dysfunction and DNA damage that may lead to cancer-cell death.